AdvaStim enters neuromodulation device market

182

AdvaStim has announced that it has entered the research and development market with a new hardware/software solution for neuromodulation therapy developers.

“AdvaStim was formed to address the multi-billion-dollar neurostimulation market with a hardware and software platform to help device companies and clinician researchers develop the next generation of implantable therapeutics,” says Laurence Derose, founder of AdvaStim.

“Our Implantable Pulse Generator technology was designed to accommodate a variety of existing and emerging clinical indications,” continues Derose. “It offers developers complete independent control over waveform current, duration, rate and phase characteristics. The system architecture is modular, providing a building-block approach for easy customisation.”

AdvaStim’s pulse generator technology is based on the company’s VLSI-based ASICore chip architecture, along with its ASIControl embedded software. This combination allows for a broad range of stimulation algorithms that can deliver variable penetration of charge to a volume of neural tissue, it says in a company release.

AdvaStim’s ASICore chip architecture allows for multi-channel switching, user-defined output energy algorithms and external sensor data. According to the company, its compact form factor can help enable a new generation of smaller, more flexible and customisable implantable pulse generators.

In the press release it says that the AdvaStim’s ASIControl embedded software gives therapy developers an enhanced range of output energy parameters. It controls modulation of current amplitude and pulse duration, and allows for multi-channel delivery of simultaneous, sequential or independent pulse rates.

“AdvaStim’s technology gives therapy developers new capabilities to shape the stimulation field and provides tools to allow them to explore the issue of neural adaptation,” states Barry Yomtov, chief technology officer and co-founder of AdvaStim. “Our technology gives developers a cost-effective platform for future growth and a faster track to prototype new therapy devices.”

(Visited 14 times, 1 visits today)